No Data
No Data
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ): Terminates restructuring matters.
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ) announced that it will hold the thirteenth director's meeting on July 10, 2024, according to the company's announcement...
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ) has not yet engaged in synthetic biology business.
On June 21, Gelunhui reported that Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ) stated on the investor interactive platform that synthetic biology is a national strategic industry with green and low-carbon features. However, the subsidiaries within the scope of consolidation of the company have not engaged in synthetic biology business.
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ): Huang Mingliang resigned as CEO and was succeeded by Song Tao.
On June 18th, Gelunhui announced that Chengdu Huasun Technology Group Inc., Ltd.'s board of directors recently received the resignation report of the company's president, Mr. Huang Mingliang, in the form of a written submission. After resigning as president, Mr. Huang Mingliang will continue to serve as the chairman of the board of directors, as well as other relevant positions under the board of directors' specialized committee, to enable strategic planning and business management integration for the company. As of the announcement disclosure date, Mr. Huang Mingliang did not directly hold any company shares. On June 18, 2024, the Thirteenth Board of Directors' Thirteenth Conference of the company approved the Appointment Proposal for the company's President, and Mr. Song Tao was appointed as the company's President.
BT Financial Report Instant Analysis: Chengdu Huasun Technology Group Inc., Ltd.'s Q1 2024: Challenges and Opportunities in Steady Development.
Chengdu Huasun Technology Group Inc., Ltd. (stock code: 000790) is a company that focuses on the pharmaceutical and health industry, dedicating itself to achieving technological innovation and international development within the industry. Despite facing multiple challenges such as the expansion of national and local alliance procurement, fierce market competition, decrease in drug prices, and rise in raw material prices in the pharmaceutical industry in 2023, Chengdu Huasun Technology performed well in the Chinese patent medicine and traditional Chinese medicine decoction piece fields. The income and profits of these sub-industries both achieved year-on-year growth, demonstrating the company's competitive advantage in specific areas. At the policy level, the country has issued a series of policy documents to support the development of the pharmaceutical and health industry, including "the 14th Five-Year Plan."
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ) holding company, Lingkai Technology, plans to apply for listing on the main board of the Hong Kong Stock Exchange.
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ) announced that Lingkai Technology Co., Ltd. in Shanghai is a participating company of Hainan Huashen Xingrui Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company, and is a national high-tech enterprise.
[BT Financial Report Momentary Analysis] In-depth Analysis of Huashen Technology's 2023 Report: Challenges and Opportunities Coexist
As an enterprise with an important position in the fields of medicine and construction steel structures, Huashen Technology (stock code: 000790) attracted market attention for its business activities in 2023. Over the past year, Huashen Technology has faced multiple challenges such as policy adjustments in the pharmaceutical industry, increased market competition, and rising raw material costs. At the same time, it is also actively seeking transformation and breakthroughs to find new growth points in the midst of change. Judging from balance and liability data, Huashen Technology's total assets increased from 1,677 billion yuan in 2022 to 2,133 billion yuan in 2023, an increase of 27.22%, showing the size of the company
No Data